Belimumab in combination with glucocorticoids and azathioprine did not lower the risk for relapse in patients with antineutrophil cytoplasm antibody-associated vasculitis.
Lutikizumab may not improve pain or inflammation in patients with knee osteoarthritis and concomitant synovitis.
Psoriatic arthritis and psoriasis were associated with significant decreases across multiple patient-reported outcomes, including quality of life and work productivity.
Researchers examined the associations of prevalent vertebral fracture identified on vertebral fracture assessment images in routine practice with incident fractures.
Researchers validated the SLE Disease Activity Score with improved sensitivity to change compared with SLE Disease Activity Index.
Bone mineral density measures were significantly greater at 3 years in postmenopausal women with comorbid osteoporosis and rheumatoid arthritis who were given vitamin D and calcium supplementation.
Sarilumab and tocilizumab have shown no clinically relevant differences in safety and tolerability outcomes.
National and international pharmacovigilance registry data pertaining to the use of biologic agents in patients with juvenile idiopathic arthritis have been combined.
One-third of patients with refractory anti-HMGCR antibodies had improved strength or other evidence of improved disease activity after rituximab treatment.
Treatment with lutikizumab did not result in significantly better improvements in hand joint pain.
